| SELECTSemaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity | Semaglutide Cardiovascular disease, Obesity / overweight | BMI ≥27 · Established CVD | Ph 3 | Completed | 833 | Jun 2023 | 19 | results |
| ELIXAEvaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) | Lixisenatide Cardiovascular disease, Type 2 diabetes | — | Ph 3 | Completed | 829 | Feb 2015 | 12 | results |
| HF-POLARISA Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity | Amycretin / zenagamtide Heart failure, Obesity / overweight | — | Ph 3 | Not yet recruiting | 825 | Jul 2029 | — | |
| MARITIME-CVEvaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | Maridebart cafraglutide / MariTide Cardiovascular disease, Obesity / overweight | BMI ≥27 | Ph 3 | Recruiting | 772 | Jun 2028 | — | |
| NCT06383390The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | Retatrutide Cardiovascular disease, Chronic kidney disease, Obesity / overweight | BMI ≥27 · Established ASCVD/CKD | Ph 3 | Active, not recruiting | 745 | Feb 2029 | 1 | |
| SURMOUNT-MMOA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | Tirzepatide Obesity / overweight | BMI ≥27 · Established CVD | Ph 3 | Active, not recruiting | 671 | Oct 2027 | 1 | |
| SURPASS-CVOTA Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes | Dulaglutide, Tirzepatide Cardiovascular disease, Type 2 diabetes | BMI ≥25 · Established CVD | Ph 3 | Completed | 635 | Jun 2025 | 4 | |
| REDEFINE 3REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | CagriSema / cagrilintide, Semaglutide Cardiovascular disease, Obesity / overweight | HbA1c 6.5-10% | Ph 3 | Active, not recruiting | 631 | Sep 2027 | — | |
| NCT01144338Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | HbA1c 6.5-10% | Ph 3 | Completed | 629 | Apr 2017 | 18 | results |
| NCT02465515Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus | Albiglutide Cardiovascular disease, Type 2 diabetes | Established CVD | Ph 4 | Completed | 607 | Feb 2018 | 7 | results |
| MARITIME-HFMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | Maridebart cafraglutide / MariTide Heart failure, Obesity / overweight | BMI ≥30 | Ph 3 | Recruiting | 605 | Jun 2028 | — | |
| NCT07241390A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) | Orforglipron Cardiovascular disease, Chronic kidney disease | Established ASCVD/CKD | Ph 3 | Recruiting | 568 | Aug 2031 | — | |
| NCT07165028A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Retatrutide, Tirzepatide MASH / NAFLD / liver fibrosis, Obesity / overweight | — | Ph 3 | Recruiting | 562 | Aug 2030 | — | |
| ESSENCEResearch Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) | Semaglutide MASH / NAFLD / liver fibrosis | — | Ph 3 | Active, not recruiting | 556 | Apr 2029 | 3 | |
| NCT06077864A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) | Survodutide Obesity / overweight | BMI ≥27 · Established CVD | Ph 3 | Active, not recruiting | 540 | May 2026 | 1 | |
| NCT06632444LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Survodutide MASH / NAFLD / liver fibrosis, Obesity / overweight | — | Ph 3 | Recruiting | 526 | Dec 2031 | — | |
| EVOKE PlusA Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) | Semaglutide Alzheimer's / cognition | — | Ph 3 | Completed | 495 | Sep 2025 | 4 | |
| SOULA Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes | Semaglutide Cardiovascular disease, Chronic kidney disease, Type 2 diabetes | HbA1c 6.5-10% | Ph 3 | Completed | 492 | Aug 2024 | 6 | results |
| NCT06632457LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis | Survodutide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥27 | Ph 3 | Recruiting | 444 | Jun 2029 | — | |
| EVOKEA Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) | Semaglutide Alzheimer's / cognition | — | Ph 3 | Completed | 444 | Sep 2025 | 3 | |
| LEADER®Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results | Liraglutide Cardiovascular disease, Type 2 diabetes | — | Ph 3 | Completed | 428 | Dec 2015 | 41 | results |
| NCT04469855Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic® | Semaglutide Type 2 diabetes | — | — | Completed | 414 | May 2025 | — | |
| FLOWA Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease | Semaglutide Chronic kidney disease, Type 2 diabetes | HbA1c ≤10% | Ph 3 | Completed | 413 | Jan 2024 | 13 | results |
| REIMAGINE 2A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | CagriSema / cagrilintide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 405 | Nov 2025 | — | |
| NCT00838903Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes | Albiglutide Type 2 diabetes | BMI 20-45 | Ph 3 | Completed | 386 | Jan 2012 | 1 | results |
| ACHIEVE-4A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk | Orforglipron Cardiovascular disease, Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 358 | Mar 2026 | — | |
| NCT00839527A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes | Albiglutide Type 2 diabetes | BMI 20-45 | Ph 3 | Completed | 358 | Jan 2012 | 3 | results |
| AMPLITUDE-OEffect of Efpeglenatide on Cardiovascular Outcomes | Efpeglenatide Cardiovascular disease, Type 2 diabetes | — | Ph 3 | Terminated | 353 | Dec 2020 | 5 | results |
| NCT00838916A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes | Albiglutide Type 2 diabetes | BMI 20-45 | Ph 3 | Completed | 337 | Jan 2012 | 4 | results |
| NCT00849056Safety and Efficacy of Albiglutide in Type 2 Diabetes | Albiglutide Type 2 diabetes | BMI 20-45 | Ph 3 | Completed | 331 | Nov 2011 | 1 | results |
| NCT07564414A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI ≥35 | Ph 3 | Recruiting | 303 | Feb 2028 | — | |
| DUAL™ IDual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 302 | May 2012 | 9 | results |
| REWINDResearching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) | Dulaglutide Cardiovascular disease, Type 2 diabetes | HbA1c ≤9.5% | Ph 3 | Completed | 300 | Aug 2018 | 18 | results |
| NCT01018173A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease | Taspoglutide Cardiovascular disease, Type 2 diabetes | — | Ph 3 | Completed | 288 | Jan 2011 | — | |
| COMBINE 1A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec | Semaglutide Type 2 diabetes | — | Ph 3 | Completed | 281 | Mar 2024 | 1 | results |
| LixiLan-OEfficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 273 | Jun 2015 | 8 | results |
| NCT00849017Safety and Efficacy Study of Albiglutide in Type 2 Diabetes | Albiglutide Type 2 diabetes | BMI 20-45 | Ph 3 | Completed | 262 | Nov 2011 | 4 | results |
| NCT05016882Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) | CagriSema / cagrilintide, NNC0194-0499, Semaglutide MASH / NAFLD / liver fibrosis | — | Ph 2 | Completed | 255 | Dec 2024 | — | |
| REDEFINE 1A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI ≥30 | Ph 3 | Active, not recruiting | 254 | Oct 2024 | 2 | |
| SUSTAIN™ 6Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes | Semaglutide Cardiovascular disease, Type 2 diabetes | — | Ph 3 | Completed | 253 | Mar 2016 | 21 | results |
| MARITIME-1Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | Maridebart cafraglutide / MariTide Obesity / overweight | BMI ≥30 | Ph 3 | Active, not recruiting | 243 | Jan 2027 | — | |
| WAYFINDStudy of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | Semaglutide MASH / NAFLD / liver fibrosis | BMI ≥23 | Ph 2 | Completed | 242 | Nov 2024 | — | results |
| PIONEER 3Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 242 | Feb 2017 | 9 | results |
| NCT05514535A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) | Semaglutide Obesity / overweight, Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 239 | Mar 2025 | — | results |
| LixiLan-LEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 236 | Jul 2015 | 10 | results |
| NCT00856986The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 233 | Apr 2010 | 3 | results |
| LIRA-PRIMEEfficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | HbA1c 7.5-9% | Ph 4 | Completed | 232 | Aug 2019 | 2 | results |
| SUSTAIN™ 4Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 231 | Sep 2015 | 12 | results |
| FOCUSA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Active, not recruiting | 229 | Nov 2027 | — | |
| PIONEER 6A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes | Semaglutide Cardiovascular disease, Type 2 diabetes | — | Ph 3 | Completed | 228 | Sep 2018 | 14 | results |
| PIONEER PLUSResearch Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes | Semaglutide Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 228 | Mar 2023 | 1 | results |
| NCT01789957Extension Study for 2993-112 | Exenatide Type 2 diabetes | — | Ph 3 | Completed | 226 | Jun 2004 | — | |
| NCT01272219Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes | Liraglutide Obesity / overweight, Prediabetes / glucose intolerance | — | Ph 3 | Completed | 226 | Mar 2013 | 17 | results |
| NCT01098539A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment. | Albiglutide Renal impairment, Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 218 | Nov 2012 | 2 | results |
| NCT00717457A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both. | Exenatide, Taspoglutide Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 216 | Mar 2011 | 1 | |
| SURPASS-4A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk | Tirzepatide Cardiovascular disease, Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 216 | Jan 2021 | 6 | results |
| SUSTAIN 11A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c ≥7.5% | Ph 3 | Completed | 210 | Feb 2021 | 1 | results |
| NCT00755287A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea. | Taspoglutide Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 210 | Dec 2010 | 1 | |
| SUSTAIN 7Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. | Dulaglutide, Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 209 | Apr 2017 | 13 | results |
| NCT00976391A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine | Albiglutide Type 2 diabetes | HbA1c ≤7% | Ph 3 | Completed | 209 | Oct 2011 | 1 | results |
| AWARD-11A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes | Dulaglutide Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 208 | May 2019 | 3 | results |
| GetGoal-Duo-2Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 199 | Dec 2014 | 3 | results |
| NCT06221969A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | CagriSema / cagrilintide, Semaglutide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 3 | Completed | 196 | Mar 2026 | — | |
| VESPER-4Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity | MET097 / PF-08653944 Obesity / overweight | BMI 27-30 | Ph 3 | Recruiting | 195 | Sep 2027 | — | |
| STRIDEA Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes | Semaglutide Cardiovascular disease, Type 2 diabetes | — | Ph 3 | Completed | 194 | Jun 2024 | 1 | results |
| COMMIT-UCMirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study | Tirzepatide Gastrointestinal (gastroparesis / short bowel / pancreatitis), Obesity / overweight | — | Ph 3 | Recruiting | 190 | Apr 2028 | — | |
| LEAD-2To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together | Liraglutide Type 2 diabetes | HbA1c 7-11% | Ph 3 | Completed | 190 | May 2007 | 18 | results |
| COMMIT-CDMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight | Tirzepatide Gastrointestinal (gastroparesis / short bowel / pancreatitis), Obesity / overweight | BMI ≥30 | Ph 3 | Recruiting | 187 | May 2028 | — | |
| MARITIME-2Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | Maridebart cafraglutide / MariTide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Active, not recruiting | 187 | Jan 2027 | — | |
| Ellipse™Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes | Liraglutide Type 2 diabetes | HbA1c 7-11% | Ph 3 | Completed | 185 | Nov 2017 | 2 | results |
| NCT07400653A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | MET097 / PF-08653944 Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Recruiting | 183 | Oct 2027 | — | |
| ADJUNCT ONE™The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes | Liraglutide Type 1 diabetes | HbA1c 7-10% | Ph 3 | Completed | 182 | Jun 2015 | 3 | results |
| NCT05013229A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3) | Semaglutide Type 2 diabetes | BMI ≤40 | Ph 3 | Completed | 182 | Nov 2023 | 1 | |
| STEP HFpEF DMResearch Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes | Semaglutide Heart failure, Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 3 | Completed | 180 | Oct 2023 | 13 | |
| REDEFINE 2A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight, Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 179 | Jan 2025 | 1 | |
| ENLIGHTEN-6A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin | Eloralintide Obesity / overweight | — | Ph 3 | Recruiting | 178 | Jun 2028 | — | |
| NCT03807440DIA_CENTRAL:T2D Treatment Pattern in Central Europe | GLP-1 / incretin class catch-all Type 2 diabetes | — | — | Completed | 177 | Aug 2021 | 1 | results |
| NCT05877547A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) | Efinopegdutide, Semaglutide MASH / NAFLD / liver fibrosis | HbA1c ≤9% | Ph 2 | Completed | 175 | Dec 2025 | — | |
| NCT01128894A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide. | Albiglutide, Liraglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 173 | Sep 2011 | 1 | results |
| ENLIGHTEN-1A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes | Eloralintide Obesity / overweight, Prediabetes / glucose intolerance | — | Ph 3 | Recruiting | 170 | Mar 2028 | — | |
| TRIUMPH-3A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease | Retatrutide Cardiovascular disease, Obesity / overweight | BMI ≥35 · Established CVD | Ph 3 | Active, not recruiting | 169 | Apr 2026 | — | |
| NCT00700817The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus | Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 166 | Jun 2009 | 14 | results |
| REIMAGINE 5A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both | CagriSema / cagrilintide, Semaglutide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 3 | Active, not recruiting | 163 | Jun 2026 | — | |
| NCT00518115Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only | Albiglutide, Exenatide Type 2 diabetes | BMI 20-40 | Ph 2 | Completed | 163 | May 2008 | 2 | results |
| NCT01272232Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes | Liraglutide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Completed | 161 | Jan 2013 | 13 | results |
| ENLIGHTEN-4Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight | Eloralintide Obesity / overweight, Osteoarthritis | — | Ph 3 | Recruiting | 160 | Mar 2028 | — | |
| ENLIGHTEN-2A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes | Eloralintide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Recruiting | 159 | Jan 2028 | — | |
| BRIGHTEfficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist | GLP-1 / incretin class catch-all Type 2 diabetes | — | Ph 4 | Completed | 158 | Aug 2017 | 1 | results |
| NCT02970942Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. | Semaglutide MASH / NAFLD / liver fibrosis, Obesity / overweight | — | Ph 2 | Completed | 158 | Feb 2020 | 7 | results |
| NCT02229227Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus | Albiglutide Type 2 diabetes | BMI ≤40 | Ph 3 | Completed | 157 | Jul 2017 | 1 | results |
| NCT04771273A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) | Survodutide MASH / NAFLD / liver fibrosis | — | Ph 2 | Completed | 154 | Nov 2023 | 1 | results |
| NCT02461589Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes | Liraglutide, Semaglutide Type 2 diabetes | BMI 25-40 | Ph 2 | Completed | 150 | Oct 2016 | 1 | results |
| GETGOAL-PGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 150 | Jun 2011 | 1 | results |
| NCT00754988A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin. | Taspoglutide Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 148 | Mar 2011 | — | |
| NCT00909597A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes | Taspoglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 147 | Nov 2010 | — | |
| NCT06717698A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease | NNC0519-0130, Semaglutide Chronic kidney disease, Obesity / overweight | — | Ph 2 | Recruiting | 147 | Sep 2026 | — | |
| STEP 2Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity | Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Completed | 147 | Mar 2020 | 6 | results |
| SURPASS-T1D-1A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Tirzepatide Obesity / overweight, Type 1 diabetes | BMI ≥25 | Ph 3 | Active, not recruiting | 146 | Nov 2026 | — | |
| STEP-HFpEFResearch Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity | Semaglutide Heart failure, Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 146 | Apr 2023 | 7 | results |
| NCT04847557A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial | Tirzepatide Heart failure, Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 146 | Jul 2024 | 7 | results |
| SUSTAIN™ 3Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes | Exenatide, Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 146 | Jul 2015 | 18 | results |
| SYNCHRONIZE™-2A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight | Survodutide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Completed | 143 | Dec 2025 | 1 | |
| DUAL™ VIIIA 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus | Liraglutide Type 2 diabetes | BMI ≥20 | Ph 3 | Completed | 143 | Oct 2018 | 2 | results |
| SUSTAIN™ 2Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 141 | Oct 2015 | 18 | results |
| GetGoal-Duo124-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 140 | Aug 2011 | 6 | results |
| ATTAIN-PADEfficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease | Orforglipron Cardiovascular disease | — | Ph 3 | Recruiting | 138 | Jun 2028 | — | |
| ATTAIN-1A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities | Orforglipron Obesity / overweight, Prediabetes / glucose intolerance | — | Ph 3 | Active, not recruiting | 138 | Jul 2025 | 1 | |
| RESTRAIN-SUIA Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight | Orforglipron Obesity / overweight, Urinary Incontinence, Stress | Female | Ph 3 | Recruiting | 137 | Mar 2028 | — | |
| VANQUISH 1VK2735 for Weight Management Phase 3 | VK2735 Obesity / overweight | BMI ≥30 | Ph 3 | Active, not recruiting | 137 | Jul 2027 | — | |
| ATTAIN-2A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Orforglipron Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Completed | 136 | Aug 2025 | 1 | |
| EAGLEEfficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure | Liraglutide Type 2 diabetes | BMI 25-40 | Ph 4 | Completed | 136 | Oct 2012 | — | results |
| COMBINE 2A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2) | Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 136 | Dec 2023 | 1 | results |
| SURPASS-6A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin | Tirzepatide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 135 | Oct 2022 | 2 | results |
| TRIUMPH-1A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight | Retatrutide Obesity / overweight, Osteoarthritis, Sleep apnea | BMI ≥30 | Ph 3 | Active, not recruiting | 134 | Apr 2026 | — | |
| NCT02229396Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo | Exenatide Type 2 diabetes | HbA1c 8-12% | Ph 3 | Completed | 133 | Apr 2016 | 4 | results |
| NCT01664247The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification | Liraglutide Type 2 diabetes | HbA1c 7.5-10% | Ph 3 | Completed | 132 | Dec 2013 | 1 | results |
| ENLIGHTEN-3A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight | Eloralintide Obesity / overweight, Sleep apnea | BMI ≥27 | Ph 3 | Recruiting | 131 | Mar 2028 | — | |
| ACHIEVE-3A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin | Orforglipron, Semaglutide Type 2 diabetes | HbA1c ≥7% | Ph 3 | Completed | 131 | Aug 2025 | 1 | |
| NCT05486065A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight | Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 2 | Completed | 130 | Oct 2023 | — | results |
| NCT05144984A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes | NNC0480-0389, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 2 | Completed | 129 | Feb 2023 | — | results |
| SUSTAIN FORTEA Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 8-10% | Ph 3 | Completed | 129 | Sep 2020 | 1 | results |
| NCT00039013Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin | Exenatide Type 2 diabetes | BMI 27-45 | Ph 3 | Completed | 129 | Jun 2003 | 4 | |
| NCT06131372A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo | CagriSema / cagrilintide, Semaglutide Chronic kidney disease, Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 2 | Completed | 128 | Sep 2025 | — | |
| STEP 1STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity | Semaglutide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 128 | Mar 2020 | 11 | results |
| LEAD-1Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 127 | May 2007 | 15 | |
| SURPASS-2A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 127 | Jan 2021 | 9 | results |
| NCT07104383VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | VK2735 Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Active, not recruiting | 127 | Jul 2027 | — | |
| NCT00039026Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea | Exenatide Obesity / overweight, Type 2 diabetes | BMI 27-45 | Ph 3 | Completed | 126 | Aug 2003 | 3 | |
| LEAD-6Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes | Exenatide, Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 125 | Apr 2008 | 16 | results |
| BEGIN™Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin | Liraglutide Type 2 diabetes | — | Ph 3 | Completed | 124 | Jul 2012 | 1 | results |
| LixiLan-GEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period | Albiglutide, Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 124 | May 2018 | 5 | results |
| NCT02229383Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus | Exenatide Type 2 diabetes | HbA1c 7.5-12% | Ph 3 | Completed | 123 | Aug 2016 | 2 | results |
| LIXILAN JP-LEfficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 122 | Oct 2018 | 1 | |
| NCT05064735Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis | Semaglutide Obesity / overweight, Osteoarthritis | BMI ≥30 | Ph 3 | Completed | 122 | Jul 2023 | 1 | results |
| NCT03596450Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial | Semaglutide Type 2 diabetes | — | Ph 4 | Completed | 122 | Jun 2022 | 2 | results |
| SURPASS-3A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes | Tirzepatide Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 122 | Dec 2020 | 9 | results |
| NCT01455857A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes | Exenatide Obesity / overweight, Type 2 diabetes | HbA1c 7.5-10% | Ph 3 | Completed | 121 | Aug 2014 | 1 | |
| AMAZE 8AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight | Amycretin / zenagamtide, Semaglutide Obesity / overweight, Type 2 diabetes | HbA1c 7-10% | Ph 3 | Not yet recruiting | 120 | Dec 2028 | — | |
| ADJUNCT TWO™The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes | Liraglutide Type 1 diabetes | HbA1c 7-10% | Ph 3 | Completed | 120 | Apr 2015 | 4 | results |
| NCT07253285A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight | — | Ph 3 | Recruiting | 119 | Mar 2030 | — | |
| SUSTAIN 8Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 119 | Oct 2018 | 5 | results |
| NCT03235050A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes | Cotadutide, Liraglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 2 | Completed | 119 | May 2018 | 1 | results |
| NCT06542874A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes | Amycretin / zenagamtide Type 2 diabetes | BMI ≤50 | Ph 2 | Completed | 119 | Oct 2025 | — | |
| SYNCHRONIZE™-1A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight | Survodutide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 118 | Dec 2025 | 1 | |
| PIONEER 8Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin | Semaglutide Type 2 diabetes | HbA1c 7-9.5% | Ph 3 | Completed | 118 | Jan 2018 | 5 | results |
| SURMOUNT-1A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight | Tirzepatide Obesity / overweight, Prediabetes / glucose intolerance | BMI ≥30 | Ph 3 | Completed | 118 | Apr 2022 | 14 | results |
| COMBINE 4A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4) | Semaglutide Type 2 diabetes | HbA1c ≥8% | Ph 3 | Completed | 118 | May 2025 | — | |
| PIONEER 5Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment | Semaglutide Renal impairment, Type 2 diabetes | HbA1c 7-9.5% | Ph 3 | Completed | 117 | Apr 2018 | 7 | results |
| LEAD-3To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c | Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Terminated | 117 | Nov 2008 | 19 | results |
| NCT02420262A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus | Liraglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 117 | Oct 2016 | 3 | results |
| NCT07357766A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight | — | Ph 3 | Not yet recruiting | 116 | Nov 2027 | — | |
| LEAD-5Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 116 | Apr 2007 | 14 | |
| PROXYMO-ADVA Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis | Cotadutide MASH / NAFLD / liver fibrosis | — | Ph 2 | Completed | 115 | Apr 2024 | — | results |
| NCT00359762Exenatide Versus Glimepiride in Patients With Type 2 Diabetes | Exenatide Obesity / overweight, Type 2 diabetes | BMI 25-40 | Ph 3 | Completed | 114 | Mar 2011 | 3 | results |
| LIXILAN JP-O2Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 113 | Mar 2018 | 1 | |
| NCT00744367A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone. | Taspoglutide Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 113 | Nov 2010 | — | |
| SYNERGY-NASHA Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) | Tirzepatide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥27 | Ph 2 | Completed | 112 | Dec 2023 | 1 | results |
| NCT06283667Special Use - Results Surveillance on Long-term Use With Wegovy® | Semaglutide Obesity / overweight | BMI ≥27 | — | Active, not recruiting | 112 | Jan 2028 | — | |
| DUAL™ IIIThe Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy | Exenatide, GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | BMI ≤40 | Ph 3 | Completed | 109 | Mar 2014 | 3 | results |
| NCT02443155A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function | Liraglutide Type 1 diabetes | — | Ph 2 | Completed | 108 | Aug 2018 | 1 | results |
| PIONEER 4Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus | Liraglutide, Semaglutide Type 2 diabetes | HbA1c 7-9.5% | Ph 3 | Completed | 108 | Aug 2017 | 7 | results |
| NCT01029886Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes | Exenatide, Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 108 | Jan 2011 | 2 | results |
| STEP UPA Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) | Semaglutide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 107 | Oct 2024 | 1 | results |
| NCT00229658An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes | Pramlintide Type 1 diabetes, Type 2 diabetes | HbA1c ≤9% | — | Completed | 107 | May 2008 | 1 | results |
| PIONEER 2Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus | Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 106 | Aug 2017 | 8 | results |
| LIRA-SWITCH™Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin | Liraglutide Type 2 diabetes | BMI ≥20 | Ph 4 | Completed | 106 | Jun 2015 | 1 | results |
| NCT00676338Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) | Exenatide Type 2 diabetes | BMI 23-45 | Ph 3 | Completed | 106 | Jul 2010 | 5 | results |
| PIONEER 1Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only | Semaglutide Type 2 diabetes | HbA1c 7-9.5% | Ph 3 | Completed | 105 | Oct 2017 | 10 | results |
| NCT05478252A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 104 | Aug 2023 | — | results |
| NCT01923181Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes | Semaglutide Obesity / overweight, Type 2 diabetes | HbA1c 7-9.5% | Ph 2 | Completed | 103 | Dec 2014 | 1 | results |
| NCT06409130Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease | CagriSema / cagrilintide, NNC0194-0499, Semaglutide Alcohol / substance use, MASH / NAFLD / liver fibrosis | — | Ph 2 | Completed | 102 | Nov 2025 | — | |
| NCT01191268A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4) | Dulaglutide Type 2 diabetes | BMI 23-45 | Ph 3 | Completed | 101 | Feb 2012 | 4 | results |
| NCT03060980Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin | Exenatide Obesity / overweight, Type 2 diabetes | BMI 25-45 | Ph 3 | Terminated | 101 | Jan 2018 | — | |
| NCT00035984Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus | Exenatide Obesity / overweight, Type 2 diabetes | BMI 27-45 | Ph 3 | Completed | 100 | Aug 2003 | 3 | |
| NCT06083675Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes | Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 3 | Withdrawn | 100 | Jan 2025 | — | |
| NCT06948422A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | Orforglipron Hypertension, Obesity / overweight | BMI ≥25 | Ph 3 | Active, not recruiting | 100 | Sep 2027 | — | |
| NCT06948435A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | Orforglipron Hypertension, Obesity / overweight | — | Ph 3 | Active, not recruiting | 99 | Sep 2027 | — | |
| SUSTAIN™ 5Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 99 | Nov 2015 | 11 | results |
| NCT06952530A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | Orforglipron Hypertension, Obesity / overweight | — | Ph 3 | Active, not recruiting | 99 | Sep 2027 | — | |
| NCT00734474A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin | Dulaglutide Type 2 diabetes | BMI 25-40 | Ph 2/3 | Completed | 99 | Jun 2011 | 7 | results |
| TRIUMPH-2A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight | Retatrutide Obesity / overweight, Sleep apnea, Type 2 diabetes | BMI ≥27 | Ph 3 | Active, not recruiting | 98 | May 2026 | — | |
| SOLSTICEEfficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus. | AZD5004 / ECC5004, Semaglutide Type 2 diabetes | BMI ≥23 | Ph 2 | Completed | 97 | Dec 2025 | — | |
| NCT01620489Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment | Liraglutide Renal impairment, Type 2 diabetes | BMI 20-45 | Ph 3 | Completed | 97 | Aug 2013 | 4 | results |
| PIONEER TEENSA Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 6.5-11% | Ph 3 | Completed | 97 | Apr 2025 | — | |
| NCT06660173A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM) | Maridebart cafraglutide / MariTide Obesity / overweight, Type 2 diabetes | BMI 23-50 | Ph 2 | Active, not recruiting | 96 | Oct 2025 | — | |
| NCT00635492CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy | Exenatide, GLP-1 / incretin class catch-all Type 2 diabetes | — | — | Completed | 96 | Dec 2011 | 2 | results |
| ATTAIN-OA PAINA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee | Orforglipron Obesity / overweight, Osteoarthritis | — | Ph 3 | Recruiting | 95 | Apr 2028 | — | |
| NCT00960661A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes | Exenatide Type 2 diabetes | BMI 25-45 | Ph 3 | Completed | 95 | Aug 2012 | 1 | results |
| SURE GERMANYA Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY) | Semaglutide Type 2 diabetes | HbA1c ≤12% | — | Completed | 95 | May 2021 | 1 | |
| NCT06326047A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes | NNC0519-0130, Tirzepatide Type 2 diabetes | HbA1c 7.5-10% | Ph 2 | Completed | 94 | Sep 2025 | — | |
| NCT06571383STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss | Semaglutide Obesity / overweight | Age 12-15 | Ph 4 | Active, not recruiting | 93 | Nov 2028 | — | |
| PIONEER 12A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 93 | Oct 2021 | 1 | results |
| NCT01658501Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM | Liraglutide Type 2 diabetes | BMI ≤45 | Ph 2 | Completed | 93 | Jul 2013 | — | |
| NCT0097693724-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years | Lixisenatide Obesity / overweight, Type 2 diabetes | BMI ≤50 | Ph 3 | Completed | 92 | Mar 2011 | — | results |
| SUSTAIN 10Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes | Liraglutide, Semaglutide Type 2 diabetes | HbA1c 7-11% | Ph 3 | Completed | 92 | Jul 2018 | 2 | results |
| AMAZE 4AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea | Amycretin / zenagamtide Obesity / overweight, Sleep apnea | — | Ph 3 | Recruiting | 91 | Jun 2028 | — | |
| NCT01126580A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3) | Dulaglutide Type 2 diabetes | BMI 23-45 | Ph 3 | Completed | 91 | Nov 2011 | 4 | results |
| DUAL™ VA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus | Liraglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 91 | Nov 2014 | 10 | results |
| NCT00082381Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin | Exenatide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 91 | Jul 2008 | 3 | results |
| NCT05579977Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity | GLP-1 / incretin class catch-all, Lotiglipron, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥23 | Ph 2 | Terminated | 90 | Jul 2023 | 2 | results |
| SURPASS-EARLYA Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes | Tirzepatide Type 2 diabetes | HbA1c 7-9.5% | Ph 4 | Active, not recruiting | 90 | Oct 2025 | 1 | |
| AWARD-1A Study in Participants With Type 2 Diabetes Mellitus | Dulaglutide, Exenatide Type 2 diabetes | BMI 23-45 | Ph 3 | Completed | 89 | Nov 2011 | 3 | results |
| LEAD-4Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 89 | Aug 2007 | 15 | |
| AWARD-7A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) | Dulaglutide Chronic kidney disease, Type 2 diabetes | BMI 23-45 | Ph 3 | Completed | 89 | Jun 2016 | 2 | results |
| ACHIEVE-1A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone | Orforglipron Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 89 | Apr 2025 | 1 | results |
| DUALTM IXA Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus | Liraglutide Type 2 diabetes | BMI ≥20 | Ph 3 | Completed | 88 | Sep 2017 | 1 | results |
| DUAL™IVThe Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy | Liraglutide Type 2 diabetes | HbA1c 7-9% | Ph 3 | Completed | 87 | Oct 2013 | 3 | results |
| TOGETHER-PsAIxekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight | Tirzepatide Obesity / overweight, Psoriasis / psoriatic arthritis | BMI ≥30 | Ph 3 | Completed | 86 | Nov 2025 | 1 | |
| SUSTAIN™1Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 86 | May 2015 | 13 | results |
| DUAL™ IIA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | HbA1c 7.5-10% | Ph 3 | Completed | 86 | Oct 2012 | 7 | results |
| NCT01617434The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI 20-45 | Ph 3 | Completed | 86 | Oct 2013 | 2 | results |
| LixiLan-DEfficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents | Lixisenatide Type 2 diabetes | HbA1c 7.5-10% | Ph 3 | Terminated | 85 | Jan 2019 | — | results |
| DUAL™ VIA Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms | Liraglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 84 | Dec 2015 | 2 | results |
| GetGoal-OEfficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients | Lixisenatide Type 2 diabetes | Age ≥70 | Ph 3 | Completed | 83 | Feb 2015 | 2 | results |
| PIONEER 7Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. | Semaglutide Type 2 diabetes | HbA1c 7.5-9.5% | Ph 3 | Completed | 83 | Feb 2018 | 7 | results |
| NCT04515849A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus | Cotadutide, Semaglutide Chronic kidney disease, Type 2 diabetes | BMI ≥25 | Ph 2 | Completed | 83 | Mar 2022 | 3 | results |
| NCT03985293A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus | Danuglipron Type 2 diabetes | BMI 24.5-45.4 | Ph 2 | Completed | 83 | Jun 2021 | 1 | results |
| AMAZE 5A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain | Amycretin / zenagamtide Obesity / overweight, Osteoarthritis | — | Ph 3 | Recruiting | 82 | Aug 2028 | — | |
| NCT01517412Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 82 | May 2013 | 1 | results |
| NCT02964247LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors. | Liraglutide Type 2 diabetes | HbA1c 7-9.5% | Ph 3 | Completed | 82 | May 2018 | 2 | results |
| AMAZE 6AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain | Amycretin / zenagamtide Obesity / overweight, Osteoarthritis | — | Ph 3 | Recruiting | 81 | Aug 2028 | — | |
| NCT06972459A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | Orforglipron Obesity / overweight | BMI ≥30 | Ph 3 | Active, not recruiting | 80 | Aug 2027 | — | |
| AMAZE 3AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea | Amycretin / zenagamtide Obesity / overweight, Sleep apnea | — | Ph 3 | Recruiting | 80 | Jul 2028 | — | |
| NCT04153929A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. | Semaglutide, Survodutide Obesity / overweight, Type 2 diabetes | BMI 25-50 | Ph 2 | Completed | 80 | Oct 2021 | 1 | results |
| NCT06972472A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | Orforglipron Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 3 | Active, not recruiting | 80 | Aug 2027 | — | |
| NCT06993792A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | Orforglipron Obesity / overweight, Type 2 diabetes | — | Ph 3 | Active, not recruiting | 80 | Aug 2027 | — | |
| SURPASS-T1D-2A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | Tirzepatide Obesity / overweight, Type 1 diabetes | BMI ≥25 | Ph 3 | Active, not recruiting | 79 | Nov 2026 | — | |
| Lixilan-O-APEvaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s) | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 79 | Mar 2021 | 2 | |
| NCT05669599Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus | Maridebart cafraglutide / MariTide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 2 | Completed | 78 | Oct 2024 | 1 | |
| AWARD-2A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2) | Dulaglutide Type 2 diabetes | BMI 23-45 | Ph 3 | Completed | 78 | May 2012 | 3 | results |
| NCT06260722Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) | Retatrutide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 3 | Active, not recruiting | 77 | Aug 2026 | — | |
| NCT00696657A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide | Liraglutide, Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 2 | Completed | 77 | Feb 2009 | 1 | results |
| DUAL™ I JapanA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus. | Liraglutide Type 2 diabetes | HbA1c 7-11% | Ph 3 | Completed | 76 | Dec 2017 | 2 | results |
| NCT05649137A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight | Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 3 | Completed | 76 | Oct 2024 | 1 | results |
| NCT06297603Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) | Retatrutide Renal impairment, Type 2 diabetes | BMI ≥23 | Ph 3 | Active, not recruiting | 76 | Oct 2026 | — | |
| NCT01149421A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes | Dulaglutide Type 2 diabetes | BMI ≥23 | Ph 2 | Completed | 76 | Sep 2011 | 1 | results |
| SURMOUNT-2A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight | Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Completed | 75 | Mar 2023 | 4 | results |
| NCT00641056Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3) | Exenatide Type 2 diabetes | BMI 25-45 | Ph 3 | Completed | 75 | May 2009 | 7 | results |
| AMAZE 2AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight | Amycretin / zenagamtide Obesity / overweight, Type 2 diabetes | HbA1c 7-10% | Ph 3 | Recruiting | 74 | Aug 2028 | — | |
| ACHIEVE-2A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin | Orforglipron Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 74 | Sep 2025 | — | |
| NCT01733758A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) | Albiglutide, Liraglutide Type 2 diabetes | BMI 17-40 | Ph 3 | Completed | 74 | Jun 2014 | — | results |
| NCT02453711Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus | Liraglutide, Semaglutide Obesity / overweight | BMI ≥30 | Ph 2 | Completed | 74 | Mar 2017 | 2 | results |
| NCT07654374A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2) | Aleniglipron / GSBR-1290 Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Not yet recruiting | 74 | Sep 2028 | — | |
| Enith1A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes | CT-388 Obesity / overweight | — | Ph 3 | Recruiting | 73 | Jul 2028 | — | |
| NCT06439277A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) | Tirzepatide Dyslipidemia, Hypertension, Obesity / overweight, Prediabetes / glucose intolerance | Age 12-17 | Ph 3 | Recruiting | 73 | Oct 2027 | — | |
| AMAZE 1AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight | Amycretin / zenagamtide Obesity / overweight | — | Ph 3 | Recruiting | 72 | Jun 2029 | — | |
| AMAZE 12AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss | Amycretin / zenagamtide Obesity / overweight | — | Ph 3 | Recruiting | 72 | Jun 2028 | — | |
| SUSTAIN 9Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus | Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 72 | Jul 2018 | 1 | results |
| STEP 4Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity | Semaglutide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 72 | Feb 2020 | 6 | results |
| TOGETHER-PsOIxekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight | Tirzepatide Obesity / overweight, Psoriasis / psoriatic arthritis | BMI ≥30 | Ph 3 | Active, not recruiting | 72 | Jan 2026 | 1 | |
| NCT07654361Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1) | Aleniglipron / GSBR-1290 Obesity / overweight | BMI ≥30 | Ph 3 | Not yet recruiting | 71 | Sep 2028 | — | |
| NCT00823992A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy | Taspoglutide Obesity / overweight, Type 2 diabetes | BMI 30-50 | Ph 3 | Completed | 71 | May 2010 | — | |
| NCT02683746Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus | Albiglutide Type 2 diabetes | BMI ≤40 | Ph 3 | Completed | 70 | Apr 2017 | 1 | results |
| NCT06628362A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus | CT-388 Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 2 | Active, not recruiting | 70 | Jun 2026 | — | |
| SURMOUNT-4A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss | Tirzepatide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 70 | Apr 2023 | 8 | results |
| ACHIEVE-5A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor | Orforglipron Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 70 | Sep 2025 | — | |
| NCT01476475Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients | Lixisenatide Type 2 diabetes | — | Ph 2 | Completed | 70 | Dec 2012 | 1 | results |
| NCT06326060A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight | NNC0519-0130, Tirzepatide Obesity / overweight | BMI ≥27 | Ph 2 | Completed | 70 | Apr 2025 | — | |
| NCT04944992A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) | Efinopegdutide, Semaglutide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥25 | Ph 2 | Completed | 69 | Oct 2022 | 1 | results |
| NCT00082407Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin | Exenatide Type 2 diabetes | BMI 25-40 | Ph 3 | Completed | 69 | Jul 2008 | 3 | results |
| NCT06465186A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) | Efinopegdutide MASH / NAFLD / liver fibrosis | — | Ph 2 | Active, not recruiting | 68 | Aug 2026 | — | |
| RENEW 2Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | CagriSema / cagrilintide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Active, not recruiting | 67 | May 2027 | — | |
| SUSTAINEfficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) | Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 67 | Mar 2019 | 2 | results |
| NCT04093752A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo) | Tirzepatide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 67 | Nov 2021 | 2 | results |
| STARS extendOpen-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. | GLP-1 / incretin class catch-all Gastrointestinal (gastroparesis / short bowel / pancreatitis) | — | Ph 3 | Active, not recruiting | 66 | Oct 2027 | — | |
| NCT06738979A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects | Semaglutide Obesity / overweight | BMI ≥28 | Ph 3 | Not yet recruiting | 66 | Jul 2026 | — | |
| NCT02973100A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy | Dulaglutide Type 2 diabetes | BMI ≥25 | Ph 2 | Completed | 66 | Jul 2017 | — | results |
| PIONEER 11A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 66 | Sep 2021 | 1 | results |
| ATTAIN-OSAA Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight | Orforglipron Obesity / overweight, Sleep apnea | BMI ≥27 | Ph 3 | Active, not recruiting | 66 | Nov 2026 | — | |
| TRIUMPH-5A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Retatrutide, Tirzepatide Obesity / overweight | — | Ph 3 | Active, not recruiting | 65 | Dec 2026 | — | |
| SURMOUNT-3A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program | Tirzepatide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 65 | Apr 2023 | 6 | results |
| NCT07415954A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 2 | Recruiting | 63 | Sep 2027 | — | |
| VISTAEffects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity | AZD5004 / ECC5004 Obesity / overweight | BMI ≥30 | Ph 2 | Completed | 62 | Nov 2025 | — | |
| NCT00637273A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2) | Exenatide Type 2 diabetes | BMI 25-45 | Ph 3 | Completed | 62 | Feb 2009 | 8 | results |
| Enith2A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes | CT-388 Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Recruiting | 61 | Aug 2028 | — | |
| NCT07357740A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes | CagriSema / cagrilintide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI 25-39.9 | Ph 2 | Not yet recruiting | 61 | Aug 2027 | — | |
| NCT04154072A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease | Exenatide Parkinson's disease | — | Ph 2 | Completed | 61 | Feb 2023 | 1 | |
| LIRA-LIXI™Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes | Liraglutide, Lixisenatide Type 2 diabetes | BMI ≥20 | Ph 4 | Completed | 61 | Nov 2014 | 2 | results |
| AWARD-PEDSA Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes | Dulaglutide Obesity / overweight, Type 2 diabetes | HbA1c 6.5-11% | Ph 3 | Completed | 61 | Jun 2021 | 2 | results |
| LIXILAN JP-O1Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 61 | May 2018 | 1 | |
| COURAGEA Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation | Semaglutide Healthy volunteers, Obesity / overweight | BMI 18-32 | Ph 2 | Active, not recruiting | 60 | May 2026 | — | |
| NCT04505436Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects | Efocipegtrutide MASH / NAFLD / liver fibrosis | BMI ≥18 | Ph 2 | Active, not recruiting | 60 | Jun 2026 | — | |
| DURATION-NEO-2Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 60 | Apr 2014 | 2 | results |
| NCT00111540Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes | Exenatide Type 2 diabetes | BMI 25-45 | Ph 3 | Completed | 60 | Sep 2006 | 5 | |
| DUAL™A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification | Liraglutide Type 2 diabetes | — | Ph 3 | Completed | 60 | Apr 2015 | — | results |
| NCT06897475A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | Semaglutide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 2 | Recruiting | 60 | Dec 2026 | — | |
| NCT05413369iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) | Lixisenatide Type 2 diabetes | BMI ≤40 | Ph 3 | Completed | 60 | Oct 2023 | — | results |
| NCT02973321A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus | Liraglutide, SAR425899 Obesity / overweight, Type 2 diabetes | — | Ph 2 | Completed | 59 | Dec 2017 | 2 | results |
| NCT00765817Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 59 | Jan 2010 | 5 | results |
| DURATION-NEO-1Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes | Exenatide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 58 | Aug 2014 | 2 | results |
| SURMOUNT-OSAObstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea | Tirzepatide Obesity / overweight, Sleep apnea | BMI ≥30 | Ph 3 | Completed | 58 | Mar 2024 | 5 | results |
| NCT00744926A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise. | Taspoglutide Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 58 | Apr 2010 | — | |
| AWARD-6A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes | Dulaglutide, Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 57 | Nov 2013 | 3 | results |
| STEP YoungA Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight | Semaglutide Obesity / overweight | HbA1c ≤10% | Ph 3 | Active, not recruiting | 56 | Oct 2025 | — | |
| MARITIME-OSA-1Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | Maridebart cafraglutide / MariTide Obesity / overweight, Sleep apnea | BMI ≥27 | Ph 3 | Recruiting | 56 | Sep 2027 | — | |
| REIMAGINEYOUNGA Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes | CagriSema / cagrilintide, Semaglutide Obesity / overweight, Type 2 diabetes | HbA1c 6.5-11% | Ph 3 | Not yet recruiting | 56 | Sep 2029 | — | |
| NCT01051011A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy | Taspoglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Terminated | 56 | Dec 2010 | — | |
| OASIS 1Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) | Semaglutide Obesity / overweight | — | Ph 3 | Completed | 56 | Mar 2023 | 1 | results |
| NCT06864026A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) | Tirzepatide Obesity / overweight, Psoriasis / psoriatic arthritis | — | Ph 4 | Recruiting | 55 | Nov 2027 | — | |
| NCT06797869A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy | CagriSema / cagrilintide, Semaglutide Diabetic neuropathy, Type 2 diabetes | BMI ≥25 | Ph 2 | Active, not recruiting | 54 | Aug 2026 | — | |
| AMPLITUDE-MEfficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise | Efpeglenatide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 54 | Jan 2020 | 1 | results |
| SCALE™ InsulinEffect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin | Liraglutide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Completed | 54 | Sep 2018 | 1 | results |
| NCT03856047Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. | CagriSema / cagrilintide, Liraglutide Obesity / overweight | — | Ph 2 | Completed | 54 | Mar 2020 | 1 | results |
| NCT01455870A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes | Exenatide Type 2 diabetes | HbA1c 7.5-10.5% | Ph 3 | Completed | 54 | Jul 2015 | — | |
| NCT00658021Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes | Exenatide Type 2 diabetes | HbA1c 6.5-10.5% | Ph 3 | Completed | 53 | Apr 2019 | — | results |
| NCT06143956A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight | Eloralintide, Macupatide, Mazdutide, Tirzepatide Obesity / overweight | — | Ph 2 | Recruiting | 53 | Sep 2027 | — | |
| SURE FRANCEA Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE) | Semaglutide Type 2 diabetes | HbA1c ≤12% | — | Completed | 53 | Sep 2021 | 1 | |
| REIMAGINE 3A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin | CagriSema / cagrilintide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 53 | Sep 2025 | — | |
| SURPASS-1A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone | Tirzepatide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 53 | Oct 2020 | 5 | results |
| TRIUMPH-6A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity | Retatrutide Obesity / overweight | — | Ph 3 | Active, not recruiting | 53 | Apr 2028 | — | |
| ASCENDA Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone | AZD6234, AZD9550 Obesity / overweight | BMI ≥30 | Ph 2 | Active, not recruiting | 53 | May 2026 | — | |
| NCT00560417Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide | Exenatide Type 2 diabetes | HbA1c ≥7% | Ph 3 | Completed | 52 | Dec 2009 | — | results |
| NCT06603571A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes | Eloralintide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 2 | Active, not recruiting | 52 | Jun 2026 | — | |
| NCT06739122A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) | Dulaglutide Obesity / overweight, Type 2 diabetes | Age 10-17 | Ph 3 | Recruiting | 51 | Dec 2027 | — | |
| NCT00099320Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin | Exenatide Type 2 diabetes | BMI 25-45 | Ph 3 | Completed | 51 | Aug 2005 | 2 | |
| NCT02119819A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes | Exenatide Type 2 diabetes | BMI 23-45 | Ph 2 | Completed | 51 | Aug 2015 | 1 | results |
| NCT01632163Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 51 | May 2015 | 2 | |
| NCT01785771A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c | Exenatide Type 2 diabetes | HbA1c 10-12% | Ph 3 | Terminated | 51 | Jan 2018 | 1 | |
| NCT03486392A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants | Efinopegdutide, Liraglutide Obesity / overweight | — | Ph 2 | Completed | 51 | Mar 2019 | — | results |
| NCT04102189A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity | Semaglutide Obesity / overweight | HbA1c ≤10% | Ph 3 | Completed | 51 | Mar 2022 | 4 | results |
| SURPASS-PEDSA Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both | Tirzepatide Obesity / overweight, Type 2 diabetes | HbA1c 6.5-11% | Ph 3 | Completed | 51 | Jul 2024 | 1 | results |
| NCT01060059Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes | Exenatide Type 2 diabetes | HbA1c ≥7% | — | Completed | 50 | May 2012 | — | results |
| NCT07112872A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes | CT-996 / RO7795081, Semaglutide Type 2 diabetes | BMI ≥23 | Ph 2 | Active, not recruiting | 50 | Nov 2026 | — | |
| ADVANCEA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | Orforglipron Obesity / overweight | Age 6-17 | Ph 3 | Recruiting | 50 | Feb 2027 | — | |
| NCT00614120Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 50 | Feb 2009 | 5 | results |
| NCT00943917Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | HbA1c 7-10% | Ph 2 | Completed | 50 | Aug 2010 | 1 | results |
| NCT06901349A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes | Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 2 | Withdrawn | 50 | Jun 2025 | — | |
| REIMAGINE 1A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise | CagriSema / cagrilintide, Semaglutide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 50 | Oct 2025 | — | |
| MARITIME-OSA-2Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | Maridebart cafraglutide / MariTide Obesity / overweight, Sleep apnea | — | Ph 3 | Recruiting | 49 | Sep 2027 | — | |
| NCT07284901Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes | HRS9531 Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Recruiting | 49 | Mar 2028 | — | |
| NCT01777282A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus | Albiglutide Type 2 diabetes | BMI 17-40 | Ph 3 | Completed | 49 | Jan 2015 | 1 | results |
| NCT00423501A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin. | Taspoglutide Type 2 diabetes | — | Ph 2 | Completed | 49 | Nov 2007 | 1 | |
| TRIUMPH-4A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee | Retatrutide Obesity / overweight, Osteoarthritis | BMI ≥27 | Ph 3 | Completed | 49 | Nov 2025 | — | |
| NCT03131687A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus | Dulaglutide, Tirzepatide Type 2 diabetes | BMI 23-50 | Ph 2 | Completed | 49 | Aug 2018 | 4 | results |
| REMODELA Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial) | Semaglutide Chronic kidney disease, Type 2 diabetes | eGFR ≥30 | Ph 3 | Completed | 49 | Nov 2024 | 3 | results |
| AMPLITUDE-SEfficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea | Efpeglenatide Type 2 diabetes | — | Ph 3 | Terminated | 48 | Nov 2020 | — | results |
| NCT06926842Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) | Petrelintide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 2 | Active, not recruiting | 48 | Aug 2026 | — | |
| NCT00108004Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus | Pramlintide Type 1 diabetes, Type 2 diabetes | HbA1c 7-11% | Ph 3 | Completed | 48 | Jun 2005 | 3 | |
| SURPASS-5A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin | Tirzepatide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 48 | Dec 2020 | 6 | results |
| NCT06354660Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) | Retatrutide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 48 | Jan 2026 | — | |
| AMPLITUDE-LEfficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s) | Efpeglenatide Type 2 diabetes | — | Ph 3 | Terminated | 47 | Nov 2020 | — | results |
| NCT02505334A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus. | Liraglutide Type 2 diabetes | HbA1c 7.5-10% | Ph 3 | Completed | 47 | May 2017 | — | results |
| NCT01940770Specific Clinical Experience Investigation for Long-term Use of Bydureon. | Exenatide Type 2 diabetes | — | — | Completed | 47 | Nov 2019 | — | |
| NCT04373967Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI 18.5-45 | Ph 3 | Unknown | 46 | Dec 2021 | — | |
| NCT06131437A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight | CagriSema / cagrilintide, Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 46 | Dec 2025 | — | |
| NCT07011667A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI ≥30 | Ph 3 | Active, not recruiting | 46 | Mar 2027 | — | |
| NCT06230523A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight | Eloralintide Obesity / overweight | BMI ≥27 | Ph 2 | Completed | 46 | May 2025 | 1 | |
| SURPASS J-monoA Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes | Dulaglutide, Tirzepatide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 46 | Mar 2021 | 6 | results |
| NCT00791479Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes | Dulaglutide Type 2 diabetes | BMI 23-40 | Ph 2 | Completed | 46 | Jan 2010 | 1 | results |
| NCT01817569Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection) | Exenatide Type 2 diabetes | — | — | Completed | 46 | Oct 2019 | — | |
| NCT07274137A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE） | MDR-001 Obesity / overweight | BMI ≥28 | Ph 3 | Not yet recruiting | 45 | Jun 2027 | — | |
| AMPLITUDE-DEfficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin | Dulaglutide, Efpeglenatide Type 2 diabetes | — | Ph 3 | Terminated | 45 | Oct 2020 | — | results |
| Lixilan-L-CNComparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 45 | Dec 2020 | 3 | |
| NCT05048719A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus | Dulaglutide, Orforglipron Type 2 diabetes | BMI ≥23 | Ph 2 | Completed | 44 | Sep 2022 | 2 | results |
| AWARD-JPNA Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes | Dulaglutide Type 2 diabetes | BMI ≥18.5 | Ph 3 | Completed | 44 | Oct 2022 | — | results |
| NCT07009860RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) | Pemvidutide Alcohol / substance use, MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥25 | Ph 2 | Recruiting | 43 | Mar 2027 | — | |
| SUSTAIN™A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 43 | Feb 2016 | 4 | results |
| NCT04667377A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight | Survodutide Obesity / overweight | BMI ≥27 | Ph 2 | Completed | 43 | Sep 2022 | 2 | results |
| NCT04867785A Study of LY3437943 in Participants With Type 2 Diabetes | Dulaglutide, Retatrutide Type 2 diabetes | HbA1c 7-10.5% | Ph 2 | Completed | 43 | Jul 2022 | 2 | results |
| STEP 10Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes | Semaglutide Obesity / overweight, Prediabetes / glucose intolerance | BMI ≥30 | Ph 3 | Completed | 43 | Jan 2023 | 1 | results |
| NCT02060383Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly | Liraglutide Diabetes (other / unspecified) | — | Ph 4 | Completed | 43 | Feb 2018 | 2 | results |
| NCT01455896A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650 | Exenatide Cardiovascular disease, Type 2 diabetes | HbA1c ≥6.5% | Ph 3 | Completed | 42 | Mar 2016 | 2 | |
| NCT05936151A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | Retatrutide Chronic kidney disease, Obesity / overweight | BMI ≥27 | Ph 2 | Completed | 42 | Oct 2025 | 1 | |
| GOALGOAL: A Research Study Looking at Long Term Blood Sugar Control in People With Type 2 Diabetes Treated With Xultophy® in Local Clinical Practice in Japan. | Liraglutide Type 2 diabetes | — | — | Completed | 42 | Oct 2022 | — | |
| NCT01557166Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea | Liraglutide Obesity / overweight, Sleep apnea | BMI ≥30 | Ph 3 | Completed | 42 | Jun 2013 | 6 | results |
| NCT00917267A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects | Exenatide Type 2 diabetes | BMI 21-35 | Ph 3 | Completed | 42 | Sep 2010 | 2 | results |
| NCT06857942A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) | Tirzepatide Obesity / overweight, Psoriasis / psoriatic arthritis | — | Ph 4 | Recruiting | 41 | May 2028 | — | |
| APRICUSA Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity | AZD6234 Obesity / overweight | BMI ≥30 | Ph 2 | Completed | 41 | Aug 2025 | — | |
| NCT00877890A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5) | Exenatide Type 2 diabetes | BMI 25-45 | Ph 3 | Completed | 41 | Oct 2009 | 5 | results |
| LIRA-Ramadan™Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI ≥20 | Ph 4 | Completed | 41 | Sep 2014 | 2 | results |
| AWARD-10A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus | Dulaglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 41 | Feb 2017 | 2 | results |
| STEP 3Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program | Semaglutide Obesity / overweight | — | Ph 3 | Completed | 41 | Mar 2020 | 6 | results |
| NCT04707313A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity | Danuglipron Obesity / overweight | BMI ≥30 | Ph 2 | Completed | 41 | Sep 2023 | 1 | results |
| STEP 5Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity | Semaglutide Obesity / overweight | — | Ph 3 | Completed | 41 | Jan 2021 | 5 | results |
| NCT01511172Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI 25-40 | Ph 2 | Completed | 41 | Dec 2002 | 2 | |
| NCT06672939A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities | Orforglipron Obesity / overweight | Age 12-17 | Ph 3 | Recruiting | 40 | Dec 2027 | — | |
| TRIUMPH-7A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | Retatrutide Obesity / overweight, Pain | BMI ≥27 | Ph 3 | Recruiting | 40 | Sep 2027 | — | |
| RENEW 1Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | CagriSema / cagrilintide Obesity / overweight | BMI ≥30 | Ph 3 | Active, not recruiting | 40 | May 2027 | — | |
| NCT07589608A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight | Eloralintide, Macupatide Obesity / overweight | — | Ph 2 | Not yet recruiting | 40 | Sep 2027 | — | |
| NCT06037252A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity | Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥35 | Ph 2 | Active, not recruiting | 40 | Jan 2026 | — | |
| ACHIEVE-JA Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes | Orforglipron Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 40 | Jun 2025 | — | |
| IMPACTIMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) | Pemvidutide MASH / NAFLD / liver fibrosis, Metabolic syndrome, Obesity / overweight | BMI ≥27 | Ph 2 | Completed | 40 | Nov 2025 | 1 | |
| AWARD-9A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes | Dulaglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 40 | Oct 2015 | 2 | results |
| ACCESSA Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity | Aleniglipron / GSBR-1290 Obesity / overweight | BMI ≥30 | Ph 2 | Active, not recruiting | 39 | Oct 2025 | — | |
| NCT00154401Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | HbA1c ≤10% | Ph 2 | Completed | 39 | Oct 2005 | 5 | |
| NCT01511198Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent | Liraglutide Obesity / overweight, Type 2 diabetes | BMI 27-42 | Ph 2 | Completed | 39 | Oct 2001 | 2 | |
| SURE ITALYA Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice | Semaglutide Type 2 diabetes | HbA1c ≤12% | — | Completed | 39 | Jul 2021 | 1 | |
| NCT05813912A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7.5-10.5% | Ph 3 | Completed | 39 | Apr 2025 | — | |
| NCT06482112Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016) | Efinopegdutide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥25 | Ph 2 | Completed | 39 | Jun 2025 | — | results |
| NCT00434954Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes | Exenatide Type 2 diabetes | BMI 25-40 | Ph 3 | Completed | 39 | Jun 2009 | 2 | results |
| NCT07215559A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes | Eloralintide, Macupatide Obesity / overweight, Type 2 diabetes | HbA1c 7.5-10.5% | Ph 2 | Recruiting | 38 | Mar 2027 | — | |
| SELECT-LIFESELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial | Semaglutide Cardiovascular disease, Obesity / overweight | — | — | Completed | 38 | Aug 2025 | — | |
| NCT03987451A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage | Semaglutide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥27 | Ph 2 | Completed | 38 | Apr 2021 | 1 | results |
| SURPASS-SWITCHA Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) | Dulaglutide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 4 | Completed | 38 | Jul 2024 | 2 | results |
| NCT04617275A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY | Danuglipron Obesity / overweight, Type 2 diabetes | — | Ph 2 | Completed | 38 | Nov 2021 | 1 | results |
| DUAL™ II JapanA Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs | Liraglutide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 38 | Nov 2017 | 3 | results |
| ACHIEVE-RAMA Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting | Orforglipron Obesity / overweight, Type 2 diabetes | HbA1c ≥7% | Ph 3 | Not yet recruiting | 37 | May 2027 | — | |
| DUAL™ II ChinaA Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) | Liraglutide Type 2 diabetes | — | Ph 3 | Completed | 37 | Mar 2019 | — | results |
| REDEFINE 6A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 37 | Jan 2025 | — | |
| NCT06309992A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD) | Survodutide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 37 | Oct 2025 | 1 | |
